90%Confidence
0Views
FDASource
2026-04-14Date
Summary
Another Class II recall for Teva's Octreotide Acetate (10 mg) due to sterility issues at the same Greek facility highlights systemic quality problems, potentially affecting multiple product lines. This could lead to broader supply shortages and damage to Teva's brand reputation in specialty pharmaceuticals.
Actionable: Evaluate alternative suppliers or competitors in the somatostatin analog market.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now